DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Optic Neuropathy - Pipeline Review, H2 2016" report to their offering.
Optic Neuropathy pipeline therapeutics constitutes close to 14 molecules. Out of which approximately 8 molecules are developed by Companies and remaining by the Universities/Institutes. The molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 1, 4 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 3 molecules, respectively.
Optic Neuropathy - Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Optic Neuropathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews of key players involved in therapeutic development for Optic Neuropathy and features dormant and discontinued projects.
Key Topics Covered:
- Introduction
- Optic Neuropathy Overview
- Therapeutics Development
- Pipeline Products for Optic Neuropathy - Overview
- Pipeline Products for Optic Neuropathy - Comparative Analysis
- Optic Neuropathy - Therapeutics under Development by Companies
- Optic Neuropathy - Therapeutics under Investigation by Universities/Institutes
- Optic Neuropathy Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Optic Neuropathy - Products under Development by Companies
- Optic Neuropathy - Products under Investigation by Universities/Institutes
- Optic Neuropathy - Companies Involved in Therapeutics Development
- Amgen Inc.
- BioAxone BioSciences, Inc.
- Inotek Pharmaceuticals Corporation
- Ironwood Pharmaceuticals, Inc.
- PharmatrophiX, Inc.
- Quark Pharmaceuticals, Inc.
- Regenera Pharma Ltd.
For more information about this report visit http://www.researchandmarkets.com/research/mjw49n/optic_neuropathy
